HC Wainwright Comments on Kura Oncology Q2 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Equities researchers at HC Wainwright issued their Q2 2025 EPS estimates for shares of Kura Oncology in a research note issued on Thursday, February 27th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.81) per share for the quarter. HC Wainwright has a “Buy” rating and a $40.00 price target on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. HC Wainwright also issued estimates for Kura Oncology’s FY2025 earnings at ($3.14) EPS, FY2026 earnings at ($3.75) EPS, FY2027 earnings at ($4.24) EPS, FY2028 earnings at ($2.34) EPS and FY2029 earnings at ($1.12) EPS.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The company had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million.

A number of other equities analysts have also issued reports on KURA. Wedbush reiterated an “outperform” rating and issued a $36.00 target price on shares of Kura Oncology in a research report on Thursday, February 27th. Scotiabank reduced their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. TD Cowen restated a “buy” rating on shares of Kura Oncology in a research report on Thursday, November 21st. BTIG Research lowered shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research report on Thursday, February 6th. Finally, Bank of America reduced their price objective on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, November 22nd. Four investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $27.13.

Kura Oncology Stock Performance

Shares of KURA opened at $7.25 on Monday. The firm has a 50-day moving average price of $8.14 and a 200 day moving average price of $13.73. The firm has a market capitalization of $563.79 million, a PE ratio of -3.07 and a beta of 0.78. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. Kura Oncology has a 52-week low of $6.98 and a 52-week high of $24.17.

Insider Buying and Selling at Kura Oncology

In other news, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. This represents a 5.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mollie Leoni sold 4,963 shares of the stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the sale, the insider now directly owns 88,253 shares of the company’s stock, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,729 shares of company stock valued at $92,307. 5.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kura Oncology

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Kura Oncology by 7.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 131,718 shares of the company’s stock valued at $1,147,000 after purchasing an additional 9,050 shares during the last quarter. Woodline Partners LP grew its stake in shares of Kura Oncology by 20.6% in the fourth quarter. Woodline Partners LP now owns 172,704 shares of the company’s stock worth $1,504,000 after acquiring an additional 29,497 shares during the last quarter. Velan Capital Investment Management LP acquired a new stake in shares of Kura Oncology in the fourth quarter worth $1,306,000. Squarepoint Ops LLC acquired a new stake in shares of Kura Oncology in the fourth quarter worth $799,000. Finally, Two Sigma Advisers LP grew its stake in shares of Kura Oncology by 147.1% in the fourth quarter. Two Sigma Advisers LP now owns 242,200 shares of the company’s stock worth $2,110,000 after acquiring an additional 144,201 shares during the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.